These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26566033)

  • 21. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers.
    Kang G; Ma F; Chen H; Yang Y; Guo S; Wang Z; Liang X; Li L; Cui F; Zhang L
    Vaccine; 2015 Aug; 33(33):4093-9. PubMed ID: 26144895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients.
    Kara IH; Yilmaz ME; Suner A; Kadiroglu AK; Isikoglu B
    Vaccine; 2004 Sep; 22(29-30):3963-7. PubMed ID: 15364445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
    Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
    Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
    Levie K; Gjorup I; Skinhøj P; Stoffel M
    Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.
    Zhu CL; Liu P; Chen T; Ni Z; Lu LL; Huang F; Lu J; Sun Z; Qu C
    Vaccine; 2011 Oct; 29(44):7835-41. PubMed ID: 21816197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
    Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
    Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 33423842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients.
    Beran J
    Expert Opin Biol Ther; 2008 Feb; 8(2):235-47. PubMed ID: 18194079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
    Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
    Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and long-term durability of intradermal recombinant hepatitis B virus vaccine among intramuscular vaccine nonresponders: A prospective study in healthcare personnel.
    Kalchiem-Dekel O; Grupel D; Bouchnik L; Sikuler E; Ben-Yakov G
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1782-7. PubMed ID: 26101816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults.
    Potsch DV; Camacho LA; Tuboi S; Villar LM; Miguel JC; Ginuíno C; Silva EF; Mendonça RM; Moreira RB; Barroso PF
    Vaccine; 2012 Sep; 30(41):5973-7. PubMed ID: 22828589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 36165374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
    Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis.
    Liu YL; Kao MT; Huang CC
    Vaccine; 2005 Jun; 23(30):3957-60. PubMed ID: 15917117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration.
    Vazquez G; Mendoza-Guevara L; Alvarez T; Aguilar A; Morales A; Rodriguez F; Solorzano F; Garcia-Lopez E; Muñoz O
    Adv Perit Dial; 1997; 13():291-6. PubMed ID: 9360702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.